$CDNA

Bickerstaff George sold $926K of CDNA

Bickerstaff George sold 20,000 shares of CareDx, Inc. (CDNA) at $46.28 ($0.93M total) on 2026-08-05.

Original reporting
SEC EDGAR · Bickerstaff George
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDNA
Neutral
low confidence
Mentioned
$CDNA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 20,000 shares at a stated price, with post-transaction holdings reported.

02

Market read

Traders may monitor insider activity, but this filing alone does not change the company’s outlook.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, signal quality is low.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralLow confidence
Context

CareDx director Bickerstaff George filed a Form 4 selling 20,000 shares at $46.2850 on 2026-08-05, totaling about $925.7K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow than a fundamental catalyst.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no accompanying company-specific news or guidance change.

Market effects

No clear sector read-through from a single director sale.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as less routine, potentially increasing short-term skepticism.

Key entities

  • CareDx, Inc.

    Subject of the Form 4 insider transaction disclosure (CDNA).

  • Bickerstaff George

    Director who sold 20,000 shares in an open-market transaction.

Related articles

$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

$CDNAHighAI 9/10

Why CareDx Stock Jumped Today

CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.

$CDNAHigh

CareDx, Inc. (CDNA): Results of Operations and Financial Condition

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdna-20260730_earningsrele.htm EX-99.1 Document Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66

$CDNAMedAI 8/10

Why Is CareDx Stock Skyrocketing Thursday? - CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) said a finalized Medicare policy preserves coverage for its transplant surveillance tests. The company reported its shares rose nearly 29% after the announcement. Medicare will cover AlloSure Kidney surveillance up to six tests in year one and four annually in years two and three, with similar maintained coverage for AlloMap/AlloSure Heart and AlloSure Lung, plus unchanged for-cause testing.